Vida Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 73)
Vida Health logo

Vida Health

LeaderHealthcare

Digital Chronic Disease Management

Vida Health is a digital chronic disease platform covering diabetes, obesity, hypertension, and depression; raised $251.5M Series F; won 2026 MedTech Breakthrough Best Virtual Care Platform award; serves Boeing and SISC.

AI VisibilityBeta
Overall Score
B73
Category Rank
#92 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
70
Perplexity
74
Gemini
76

About

Vida Health is a San Francisco-based digital health company that delivers personalized, technology-driven care for chronic conditions including diabetes, obesity, hypertension, high cholesterol, and depression. Founded on the premise that managing chronic disease requires both clinical expertise and sustained behavioral change, Vida combines licensed physicians, registered dietitians, expert health coaches, and licensed therapists with a digital platform that integrates biometric devices, continuous monitoring, and synchronous video care. Members receive individualized treatment plans and connect with their care team through video visits and secure in-app messaging.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

73
Overall Score
93
#92
Category Rank
#1
85
AI Consensus
80
stable
Trend
stable
70
ChatGPT
94
74
Perplexity
89
76
Gemini
94
71
Claude
92
72
Grok
98

Key Details

Category
Digital Chronic Disease Management
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.